Search results
Results from the WOW.Com Content Network
Features associated with poor prognosis include a large primary tumor (over 5 cm across), high grade disease, co-existent neurofibromatosis, and the presence of metastases. [5] It is a rare tumor type, with a relatively poor prognosis in children. [6] In addition, MPNSTs are extremely threatening in NF1.
A schwannoma (or neurilemmoma) is a usually benign nerve sheath tumor composed of Schwann cells, which normally produce the insulating myelin sheath covering peripheral nerves. Schwannomas are homogeneous tumors, consisting only of Schwann cells.
Post-surgical radiotherapy has shown some promise in improving recurrence-free survival in intermediate and high grade tumors. [1] Chemotherapy for malignant spinal nerve sheath tumors has shown mixed results and is typically only used in patients in which surgery is not an option, or with aggressive or metastatic disease. [1]
New and more precisely defined entities include malignant melanotic nerve sheath tumor (formerly known as melanotic schwannoma) and hybrid nerve sheath tumors. [4] [5] The majority of peripheral nerve tumors are benign tumors of the nerve sheath (usually schwannomas); on rare occasions, they are metastatic tumors or originate from the nerve cells.
A 2009 meta-analysis of randomized controlled trials found a small difference in survival rates favoring wide excision of primary cutaneous melanomas, but these results were not statistically significant. [108] Mohs surgery has been reported with cure rate as low as 77% [109] and as high as 98.0% for melanoma-in-situ. [110]
In the United States there has been an increase in the 5-year relative survival rate between people diagnosed with cancer in 1975-1977 (48.9%) and people diagnosed with cancer in 2007-2013 (69.2%); these figures coincide with a 20% decrease in cancer mortality from 1950 to 2014. [8]
5.1 Schwannoma 5.2 Neurofibroma ... 8.1 Diffuse meningeal melanocytic neoplasms ... Toggle the table of contents.
The concept of grading of the tumors of the central nervous system, agreeing for such the regulation of the "progressiveness" of these neoplasias (from benign and localized tumors to malignant and infiltrating tumors), dates back to 1926 and was introduced by P. Bailey and H. Cushing, [1] in the elaboration of what turned out the first systematic classification of gliomas.